Stock chart
Analyses on Medipower (4)
- May 15, 2026
- March 27, 2026March 27, 2026
- Follow-up
Medipower: Do the 16-asset portfolio and the 7-asset deal actually improve returns after financing
Based on the disclosed numbers, both Medipower acquisition moves still look positive after debt cost, but not with the same strength: the 16-asset portfolio looks more comfortable, while the 7-asset deal rests on a much thinner spread.
- Follow-up
Medipower: How much of the new NOI actually reaches shareholders after Phoenix and the minority layers
Medipower’s new NOI opportunity is very large at the asset level, but the bridge to listed shareholders is much shorter: even before debt, corporate costs, and tax, the economics are already split away through local partners, non-controlling interests, and Phoenix.
Medipower 2025: The legacy portfolio is stable, but 2026 will be decided by financing and integration
Medipower enters 2026 with a stable legacy portfolio, a liquidity cushion built through debt issuance, and a large acquisition pipeline with Phoenix, but shareholder value will be determined more by closing speed and integration of the new deals than by the existing portfolio.
More companies in Investment-Properties Abroad (43)
